Akanda

Akanda Equity Ratio

The Equity Ratio of Akanda (AKAN) as of Oct 25, 2026 is -174.08 %. In the previous year, Equity Ratio was 54.04 % — a change of -422.14% (lower).

Equity Ratio

-174.08 %

YoY

-422.14%

Last updated:

Equity Ratio of Akanda is 2025 -174.08 % . Equity Ratio of Akanda was 2024 54.04 % . It decreases by -422.14% lower compared to the previous year.

The Akanda Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2020
-117.71 USD
Jan 1, 2021
-27.36 USD
Jan 1, 2022
68.98 USD
Jan 1, 2023
-43.31 USD
Jan 1, 2024
54.04 USD
Jan 1, 2025
-174.08 USD
The Akanda Equity Ratio history
YEAREquity RatioYoY
-174.08 %-422.14%
54.04 %-224.76%
-43.31 %-162.79%
68.98 %-352.12%
-27.36 %-76.76%
-117.71 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

Equity Ratio of Akanda is -174.08 % in 2025.

Equity Ratio of Akanda changed from 54.04 % to -174.08 %, representing a -422.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Akanda since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Akanda with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Akanda

All Key Metrics — Akanda